SCHEMBL5219307

SCHEMBL5219307

COC(=O)c1coc(Cc2c(Cl)cccc2Cl)n1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 1/20 0.42
SLC6A4 P31645 1/20 0.42
SLC6A3 Q01959 1/20 0.42
CDK5 Q00535 3/20 0.41
CDK5R1 Q15078 3/20 0.41
DAGLA Q9Y4D2 1/20 0.41
ALDH1A1 P00352 3/20 0.40
CACNA1G O43497 3/20 0.40
ABL1 P00519 1/20 0.40
SRC P12931 1/20 0.40
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
KMT2A Q03164 2/20 0.40
MEN1 O00255 1/20 0.40
CCNA2 P20248 2/20 0.39
CDK2 P24941 2/20 0.39
CCNA1 P78396 2/20 0.39
POLB P06746 3/20 0.39
MAPT P10636 1/20 0.38
TSHR P16473 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5213833 0.83 KDM4E (0.43) CDK5CDK5R1KMT2AMEN1CCNA2
SCHEMBL11910637 0.79 DAGLA (0.55) SLC6A2SLC6A4SLC6A3DAGLAALDH1A1
SCHEMBL14422264 0.77 SMN1; SMN2 (0.47) ALDH1A1NPC1RAB9APOLBMAPT
SCHEMBL393999 0.76 DAGLA (0.42) SLC6A2SLC6A4SLC6A3DAGLACACNA1G
SCHEMBL14422265 0.76 HDAC1 (0.43) ALDH1A1NPC1RAB9AKMT2AMEN1
SCHEMBL15001329 0.75 SLC6A2 (0.45) SLC6A2SLC6A4SLC6A3DAGLACACNA1G
SCHEMBL16130104 0.75 DAGLA (0.43) SLC6A2SLC6A4SLC6A3DAGLACACNA1G
SCHEMBL2116168 0.75 DAGLA (0.43) SLC6A2SLC6A4SLC6A3DAGLAALDH1A1
SCHEMBL1706233 0.74 LOXL2 (0.44) SLC6A2SLC6A4SLC6A3DAGLACACNA1G
SCHEMBL1975554 0.74 KLKB1 (0.56) SLC6A2SLC6A4SLC6A3DAGLAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7265138-B2 Vanilloid receptor ligands and their use in treatments AMGEN INC. (US) 2007-09-04 US disclosed
US-7265138-B2 Vanilloid receptor ligands and their use in treatments AMGEN INC. (US) 2007-09-04 US disclosed
US-7265138-B2 Vanilloid receptor ligands and their use in treatments AMGEN INC. (US) 2007-09-04 US disclosed
EP-1818333-A1 Vanilloid receptor ligands and their use in treatments Amgen Inc. (US) 2007-08-15 EP disclosed
EP-1818333-A1 Vanilloid receptor ligands and their use in treatments Amgen Inc. (US) 2007-08-15 EP disclosed
EP-1603905-A1 VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS AMGEN INC. (US) 2005-12-14 EP disclosed
WO-2004072068-A1 VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS AMGEN INC. (US) 2004-08-26 WO disclosed
US-20040157845-A1 Vanilloid receptor ligands and their use in treatments AMGEN INC. 2004-08-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040157845-A1 Vanilloid receptor ligands and their use in treatments TRPV1, TRPV2, TRPV3 SLC6A2 857/4885SLC6A4 689/4885SLC6A3 1130/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.